Macrophage Colony‐stimulating Factor Prevents Febrile Neutropenia Induced by Chemotherapy

There are very few studies describing the preventive effect of macrophage colony‐stimulating factor (M‐CSF/CSF‐1) on chemotherapy‐induced infection. In this study, we evaluated the changes in superoxide anion production by granulocytes before and after chemotherapy in ovarian cancer patients and investigated the preventive effect of M‐CSF on chemotherapy‐induced febrile neutropenia. Three courses of chemotherapy [paclitaxel 180 mg/m(2) and carboplatin (area under the curve; AUC 5)] were administered to 32 ovarian cancer patients, and seven patients presented febrile neutropenia. In the 25 afebrile patients, the percentage of superoxide anion production by granulocytes was significantly decreased from 86.5±7.7 (%) to 75.1±8.8 (%) at day 7 and 71.0±6.3 (%) at day 14 without administration of CSF. However, in the patients who presented febrile neutropenia, it was more severely decreased from 86.8±6.8 (%) to 60.0±9.9 (%) at day 7 and 56.8±5.0 (%) at day 14 without administration of CSF. When M‐CSF was administered to all patients in the next course with the same dose of chemotherapy, the incidence of febrile neutropenia was significantly decreased (P=0.0195), and the duration of fever (≫38.0°C) and high serum C‐reactive protein (CRP) (≫2.0 mg/dl) were also significantly shortened (P=0.0023, P=0.0051). Moreover, in these M‐CSF‐treated patients, the percentage of superoxide anion production by granulocytes was maintained at the level before chemotherapy. These findings indicate that severe impairment of granulocyte function leads to febrile neutropenia, and that M‐CSF reduces the incidence of febrile neutropenia by maintaining or improving granulocyte function.